Anebulo Pharmaceuticals, Inc. reported earnings results for the full year ended June 30, 2022. For the full year, the company reported net loss was USD 6.83 million compared to USD 30.25 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 2.83 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.17 USD | +0.23% | +5.85% | -10.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.33% | 56.28M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- ANEB Stock
- News Anebulo Pharmaceuticals, Inc.
- Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022